Sakaguchi Koji, Kosaka Makoto, Yamazaki Yoshitaka
Dept. of Chest Surgery, Nagano Prefectural Shinshu Medical Center.
Gan To Kagaku Ryoho. 2020 May;47(5):819-821.
An 81-year-old man was admitted to our medical center for dyspnea. He underwent right upper lobectomy due to squamous cell lung cancer 5 years ago. Chest computed tomography(CT)revealed stenosis ofthe right main bronchus, and pathological diagnosis ofthe lesion was squamous cell carcinoma and PD-L1 expression was low(tumor proportion score [TPS]: 1%). Because his performance status(PS)was 1, he underwent 4 courses ofnab -paclitaxel(nab-PTX)plus carboplatin( CBDCA)plus pembrolizumab chemotherapy and pembrolizumab maintenance chemotherapy. The stenosis ofthe right main bronchus was clear after chemotherapy, and his dyspnea was improved. Chemotherapy using nab-PTX plus CBDCA plus pembrolizumab may become one of the therapeutic choices for the recurrence after operation of an elderly person with squamous cell lung carcinoma and low PD-L1 expression.
一名81岁男性因呼吸困难入住我院医疗中心。他5年前因鳞状细胞肺癌接受了右上叶切除术。胸部计算机断层扫描（CT）显示右主支气管狭窄，病变的病理诊断为鳞状细胞癌，且程序性死亡受体配体1（PD-L1）表达较低（肿瘤比例评分 [TPS]：1%）。由于他的体能状态（PS）为1，他接受了4个疗程的白蛋白结合型紫杉醇（nab-PTX）联合卡铂（CBDCA）加帕博利珠单抗化疗以及帕博利珠单抗维持化疗。化疗后右主支气管狭窄情况明显改善，他的呼吸困难也有所好转。对于老年鳞状细胞肺癌且PD-L1表达较低的患者，术后复发使用nab-PTX联合CBDCA加帕博利珠单抗进行化疗可能成为治疗选择之一。
